Aridis Pharmaceuticals, Inc. was a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAbs) to treat life-threatening infections. The company's pipeline included innovative treatments for diseases such as ventilator-associated pneumonia (VAP) and cystic fibrosis. Aridis utilized its proprietary MabIgX® technology platform for discovering and developing human mAbs. In late 2023, Aridis Pharmaceuticals filed for Chapter 11 bankruptcy protection and subsequently sold its key assets to various entities in early 2024.
The headquarters served as the central hub for research and development, clinical trial management, and corporate operations before the company's bankruptcy and asset sales.
The facility likely housed advanced laboratories for antibody discovery, process development, and analytical testing capabilities essential for biopharmaceutical research.
As a research-focused biopharmaceutical company, the culture was likely science-driven, innovative, and collaborative, with a strong emphasis on addressing unmet medical needs in infectious diseases. Post-bankruptcy, operations at this specific site under Aridis name have ceased or been significantly reduced.
Located within the San Francisco Bay Area, a prominent biotech hub, providing access to a skilled talent pool, research institutions, and potential collaborators. This significance has diminished following the company's restructuring.
Prior to its bankruptcy, Aridis Pharmaceuticals, while headquartered in the US, engaged in activities with global implications, such as planning and conducting clinical trials which often involve international sites and collaborations. Its product candidates were aimed at addressing global health threats. Post-asset sales, its direct global operational presence as Aridis is minimal.
15721 Collection Drive
Los Gatos
CA
USA
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Aridis Pharmaceuticals' leadership includes:
Aridis Pharmaceuticals has been backed by several prominent investors over the years, including:
Following Aridis Pharmaceuticals' Chapter 11 bankruptcy filing in November 2023 and subsequent asset sales in early 2024, significant changes occurred in the executive team, with most, if not all, key executives departing from the original Aridis entity.
Discover the tools Aridis Pharmaceuticals uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Prior to its operational wind-down, Aridis Pharmaceuticals likely used standard corporate email formats. The most common formats are variations of first name, last name, and initials.
[first_initial][last]@aridispharma.com (e.g., jdoe@aridispharma.com) or [first].[last]@aridispharma.com
Format
vtruong@aridispharma.com
Example
20%
Success rate
Armata Pharmaceuticals Press Release • April 1, 2024
Armata Pharmaceuticals announced it has acquired from Aridis Pharmaceuticals its Pseudomonas aeruginosa monoclonal antibody (mAb) candidate, AR-320 (now AP-PA03), along with an exclusive license to a portfolio of other anitbody candidates....more
PR Newswire / Aridis Pharmaceuticals • February 12, 2024
Aridis Pharmaceuticals, Inc. announced the closing of the sale of its AR-301 (tosatoxumab) and AR-101 (panobacumab) assets to the Serum Institute of India Private Limited (SIIPL)....more
GlobeNewswire / Aridis Pharmaceuticals • November 15, 2023
Aridis Pharmaceuticals, Inc. announced that it and its wholly-owned subsidiary, Aridis Pharmaceuticals (Europe) Limited, have voluntarily filed for relief under Chapter 11 of the Bankruptcy Code in the District of Delaware. The Company intends to use the proceedings to facilitate a sale of its assets....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Aridis Pharmaceuticals, are just a search away.